This trial has been completed.

Conditions geriatrics, cancer
Treatment cognitive evaluation by mms (mini-mental state examination) and moca (montreal cognitive assessment) tests
Sponsor Centre Francois Baclesse
Start date September 2015
End date March 2017
Trial size 66 participants
Trial identifier NCT02558907, MoCA


Compare neurocognitive testing MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) to candidates aged patients with 1st line treatment of their cancer will be received an examination oncogériatric

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

proportion of patients with cognitive disorders identified by the MoCA or the MMSE prior to treatment
time frame: before their first treatment for the cancer, at inclusion

Eligibility Criteria

All participants at least 71 years old.

Inclusion Criteria: - Patient old over 70 years - Patient with cancer (solid tumor or hematological) for which a 1st line treatment is planned - Patient candidate an oncogeriatric assessment - Patient agreeing to participate in the study - French language - Lack of subsequent neurological sequelae with cognitive impact stroke, dementia or progressive psychiatric disorder - Patient having a life expectancy ≥ 6 months Exclusion Criteria: - Primitive cancer of the central nervous system or brain metastasis - Patients unable to meet the cognitive tests - Refusal to participate - Realization of a MMSE or MoCA test in the last 6 months

Additional Information

Official title Comparison of MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) in Cognitive Assessment in Geriatric Oncology
Principal investigator Heidi LAVIEC, MD
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Centre Francois Baclesse.